智通财经APP获悉，九源基因(02566)涨超6%，截至发稿，涨6.27%，报9.66港元，成交额852.32万港元。
消息面上，近日，九源基因发布公告，马来酸阿伐曲泊帕片(商标名：吉立欣®)(吉立欣®)已获中华人民共和国国家药品监督管理局(国家药监局)批准上市，适用于择期行诊断性操作或者手术的慢性肝病相关血小板减少症的成年患者；既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者，使血小板计数升高并减少或防止出血。
吉立欣®是新一代口服促血小板生成素受体激动剂(TPO-RA)，通过刺激骨髓祖细胞中巨核细胞的增殖和分化，进而增加血小板的生成。马来酸阿伐曲泊帕片作为口服制剂，不受食物种类的限制，便于患者服用，无需频繁的静脉输注或注射，极大地提升了患者的依从性和生活品质。
2025年，马来酸阿伐曲泊帕片进入国家医保乙类目录。公司获得吉立欣®药品注册证书，将丰富公司在血小板减少症治疗领域的产品储备，满足治疗患者不同用药需求，同时为患者提供更优的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.